This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Dermatology
  • /
  • Th17 cells and IL-17 A Focus on immunopathogenesis...
Journal

Th17 cells and IL-17 A Focus on immunopathogenesis and immunotherapeutics

Read time: 1 mins
Published:1st Oct 2013
Availability: Free full text
Ref.:Semin Arthritis Rheum. 2013 Oct;43(2):158-70.
DOI:10.1016/j.semarthrit.2013.04.006.

IMPORTANCE: Accumulating evidence suggests that IL-17 A has broad pathogenic roles in multiple autoimmune and immune-mediated inflammatory diseases, including psoriasis and rheumatoid arthritis (RA). The development of new therapies that inhibit IL-17 pathway signaling is of clinical significance.

OBJECTIVES: This review aims to summarize the current preclinical evidence on the role of Th17 cells and IL-17 and related cytokines in immune-mediated disease pathophysiology, with a focus on psoriasis and rheumatoid arthritis, as well as to summarize recent clinical trials in these indications with newly developed IL-17 pathway inhibitors.

METHODS: A systematic literature search was conducted of PubMed using relevant keywords. Studies were assessed according to recent relevance to IL-17-mediated pathophysiology and clinical IL-17 inhibition. Experimental animal models of autoimmune disease and clinical studies that focused on IL-17 pathway inhibitors were included.

RESULTS: Preclinical studies suggest that IL-17A is an attractive therapeutic target. Several IL-17A inhibitors have advanced into clinical trials, including the anti-IL-17A monoclonal antibodies, secukinumab and ixekizumab, and the anti-17RA monoclonal antibody brodalumab. Each has shown variable and sometimes favorable results in proof-of-concept and phase II clinical trials and is currently undergoing further clinical evaluation in a range of immune-mediated diseases.

CONCLUSION: Targeting the IL-17 pathway shows promise as strategy to treat immune-mediated diseases ranging from skin to joints.

 

Read abstract on library site

Access full article